8-K

                        UNITED STATES
             SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549


                          FORM 8-K



                       CURRENT REPORT
           PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

  Date of Report (Date of earliest event reported): December 1, 2003


                Global Life Sciences, Inc.
           -------------------------------------
   (Exact Name of Registrant as Specified in Its Charter)

                         Nevada
                   -------------------
       (State or other jurisdiction of incorporation)


         000-33333                         37-9374101
     ------------------            ---------------------------
  (Commission File Number)     (I.R.S. Employer Identification No.)


  2020 Main Street, Suite 600, Irvine, California      92614
 -------------------------------------------------    -------
     (Address of Principal Executive Offices)        (Zip Code)


                         949-223-7103
                    ------------------------
    (Registrant's Telephone Number, including area code)


                       Too Gourmet, Inc.
                  ----------------------------
  (Former Name or Former Address, if Changed Since Last Report)






                            - 1 -





Item 2.   Acquisition or Disposition of Assets.

       On November 18, 2003, Global Life Sciences, Inc., a
Nevada corporation (the "Registrant"), received a non-
binding Letter of Intent to acquire 90% of the outstanding
stock of Technica Entwicklungsgesesllschaft mbH & Co. KG
("Technica") from Technica's management.  Technica is
located in Ratzeburg, Germany.  The transaction is subject
to due diligence review, negotiations and drafting of the
definitive purchase agreement, which includes
representations and warranties standard for a transaction of
this nature and magnitude. Terms of the proposed
transaction have not been disclosed.

       Technica is a designer, manufacturer and distributor
of proprietary devices, equipment and apparatus produced and
developed for a variety of medical, commercial and industrial
customers, including a leading soft drink producer and an
international water producer.  A copy of Registrant's press
release is attached as Exhibit 99.1 on this reporting
Form 8-K.

Item 7.   Financial Statements and Exhibits

a.   Financial Statements

     None.

b.   Pro forma Financial Information

     None.

c.   Exhibits.

99.1 Global Life Sciences, Inc. December 1, 2003 Press
     Release concerning Letter of Intent.












                            - 2 -





                         SIGNATURES

     Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.

                         GLOBAL LIFE SCIENCES, INC.


December 1, 2003              By: /s/ Harrysen Mittler
                                  ----------------------
                              Harrysen Mittler
                              Chief Financial Officer
































                            - 3 -





Exhibit Index.

99.1 Global Life Sciences, Inc. December 1, 2003 Press
     Release concerning Letter of Intent.





































                            - 4 -

EX-99

GLOBAL LIFE SCIENCES, INC. RECEIVES LETTER OF INTENT FROM MEDICAL
                       DEVICE MANUFACTURER


Irvine, California December 1, 2003:  Global Life Sciences, Inc.,
- -OTC:GBLS is pleased to announce that it recently received a non-
binding Letter of Intent to acquire 90% of the outstanding stock
of Technica Entwicklungsgesesllschaft mbH & Co. KG ("Technica")
from its management.  Technica is located in Ratzeburg, Germany.
The transaction is subject to due diligence review, negotiations
and drafting of the definitive purchase agreement, which includes
representations and warranties standard for a transaction of this
nature and magnitude.  Terms of the proposed transaction have not
been disclosed.

Technica is a designer, manufacturer and distributor of
proprietary devices, equipment and apparatus produced and
developed for a variety of medical, commercial and industrial
customers including a leading soft drink producer and an
international mineral water producer.  According to Prof.
Reimann, Chairman of Global Life Sciences, Inc., during calendar
year 2003 Technica anticipates revenues of approximately $7.5
million and pre-tax earnings of approximately $2.0 million.
During calendar year 2004, Technica anticipates revenues of
approximately $10.0 million and pre-tax earnings of approximately
$2.5 million.

"Technica's growth for 2004-2005 is based on its existing product
pipeline which includes commercially marketable technologies and
devices that could be manufactured and commercially released
during the first quarter of 2004", said Prof. Reimann, Chairman.
"In addition, Technica will be the exclusive manufacturer of
Global Life Sciences, Inc.'s new Tabox devices, which we
currently operate and distribute in Germany.  We anticipate that
Technica will significantly strengthen our production and
distribution capacities for our medical devices in the European
Union.  In addition, Technica's fiscal performance could
significantly impact our revenues and earnings as early as the
first quarter of 2004".  The acquisition is currently anticipated
to be completed at or about the end of 2003.

About Global Life Sciences, Inc.:

Global Life Sciences, Inc., owns and operates a medical
laboratory specializing in the research, analysis, and in vitro
diagnosis of live biopsy tissue samples for allergic,
immunological, and environmentally related disorders.  In order
to improve the quality of test results, Prof. Reimann, the
company's Chairman, Chief Executive Officer, and President,
developed and patented a unique device known as a "Tabox", which
enables the precise analysis of the effects of allergens and
toxins on the human body in an in vitro environment.

Currently, the company operates a total of 28 inter-clinic Tabox
systems as proprietary devices, which are available to
practitioners, clinics and other medical customers on a fee-for-
service basis. The company anticipates the production and use of
up to 100 Tabox systems by its medical customers by the end of
the third quarter 2004. In addition, new labs, research
facilities and integrated out-patient clinics are currently
projected to be established in Zurich (Switzerland) and Berlin
(Germany) during 2004 and 2005.

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements.  Certain
information included in this press release contains statements
that are forward-looking, such as statements related to the
future anticipated direction of the industry, plans for future
expansion, various business development activities, planned
capital expenditures, future funding sources, anticipated sales
growth, and potential contracts.  Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future and,
accordingly, such results may differ from those expressed in any
forward-looking statements made by, or on behalf of Too Gourmet,
Inc.  These risks and uncertainties include, but are not limited
to, those relating to development and expansion activities,
dependence on existing management, financing activities, and
domestic and global economic conditions.

Investor Contact:
Global Life Sciences, Inc.
Attention:  c/o  R. Katz
Phone:  949-223-7103

Business Contact:
Global Life Sciences, Inc.
Attention:  Prof. Dr. Reimann
Fax:  +49-40-360-338-7380